Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Lynch, Gordon S
2001.
Novel therapies for muscular dystrophy and other muscle wasting conditions.
Expert Opinion on Therapeutic Patents,
Vol. 11,
Issue. 4,
p.
587.
Walter, Maggie C
and
Lochmüller, H
2001.
Novel approaches to treat muscular dystrophies.
Expert Opinion on Investigational Drugs,
Vol. 10,
Issue. 4,
p.
695.
Lynch, Gordon S.
Hinkle, Richard T.
Chamberlain, Jeffrey S.
Brooks, Susan V.
and
Faulkner, John A.
2001.
Force and power output of fast and slow skeletal muscles from mdx mice 6‐28 months old.
The Journal of Physiology,
Vol. 535,
Issue. 2,
p.
591.
Ryall, James G.
Gregorevic, Paul
Plant, David R.
Sillence, Martin N.
and
Lynch, Gordon S.
2002.
β2-Agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol.
American Journal of Physiology-Regulatory, Integrative and Comparative Physiology,
Vol. 283,
Issue. 6,
p.
R1386.
GREGOREVIC, PAUL
WILLIAMS, DAVID A.
and
LYNCH, GORDON S.
2002.
Hyperbaric oxygen increases the contractile function of regenerating rat slow muscles.
Medicine & Science in Sports & Exercise,
Vol. 34,
Issue. 4,
p.
630.
GREGOREVIC, PAUL
WILLIAMS, DAVID A.
and
LYNCH, GORDON S.
2002.
Hyperbaric oxygen increases the contractile function of regenerating rat slow muscles.
Medicine & Science in Sports & Exercise,
Vol. 34,
Issue. 4,
p.
630.
Liu, Mingju
Yue, Yongping
Harper, Scott Q.
Grange, Robert W.
Chamberlain, Jeffrey S.
and
Duan, Dongsheng
2005.
Adeno-Associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury.
Molecular Therapy,
Vol. 11,
Issue. 2,
p.
245.
Ryall, James G
Sillence, Martin N
and
Lynch, Gordon S
2006.
Systemic administration of β2‐adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses.
British Journal of Pharmacology,
Vol. 147,
Issue. 6,
p.
587.
Radley, H.G.
De Luca, A.
Lynch, G.S.
and
Grounds, M.D.
2007.
Duchenne muscular dystrophy: Focus on pharmaceutical and nutritional interventions.
The International Journal of Biochemistry & Cell Biology,
Vol. 39,
Issue. 3,
p.
469.
Lynch, Gordon S.
and
Ryall, James G.
2008.
Role of β-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease.
Physiological Reviews,
Vol. 88,
Issue. 2,
p.
729.
Goyenvalle, Aurélie
Babbs, Arran
Powell, Dave
Kole, Ryszard
Fletcher, Sue
Wilton, Steve D
and
Davies, Kay E
2010.
Prevention of Dystrophic Pathology in Severely Affected Dystrophin/Utrophin-deficient Mice by Morpholino-oligomer-mediated Exon-skipping.
Molecular Therapy,
Vol. 18,
Issue. 1,
p.
198.
Yin, HaiFang
Moulton, Hong M
Betts, Corinne
Merritt, Thomas
Seow, Yiqi
Ashraf, Shirin
Wang, QingSong
Boutilier, Jordan
and
Wood, Matthew JA
2010.
Functional Rescue of Dystrophin-deficient mdx Mice by a Chimeric Peptide-PMO.
Molecular Therapy,
Vol. 18,
Issue. 10,
p.
1822.
Kostrominova, Tatiana Y.
Hassett, Cheryl A.
Rader, Erik P.
Davis, Carol
Larkin, Lisa M.
Coleman, Scott
Oleson, Frederick B.
and
Faulkner, John A.
2010.
Characterization of skeletal muscle effects associated with daptomycin in rats.
Muscle & Nerve,
Vol. 42,
Issue. 3,
p.
385.
Das, Rosalina
Rich, Jason
Kim, H. Mike
McAlinden, Audrey
and
Thomopoulos, Stavros
2011.
Effects of botulinum toxin‐induced paralysis on postnatal development of the supraspinatus muscle.
Journal of Orthopaedic Research,
Vol. 29,
Issue. 2,
p.
281.
Percival, Justin M
Whitehead, Nicholas P
Adams, Marvin E
Adamo, Candace M
Beavo, Joseph A
and
Froehner, Stanley C
2012.
Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.
The Journal of Pathology,
Vol. 228,
Issue. 1,
p.
77.
Joassard, Olivier R.
Durieux, Anne-Cécile
and
Freyssenet, Damien G.
2013.
β2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders.
The International Journal of Biochemistry & Cell Biology,
Vol. 45,
Issue. 10,
p.
2309.
Guiraud, Simon
Squire, Sarah E.
Edwards, Benjamin
Chen, Huijia
Burns, David T.
Shah, Nandini
Babbs, Arran
Davies, Stephen G.
Wynne, Graham M.
Russell, Angela J.
Elsey, David
Wilson, Francis X.
Tinsley, Jon M.
and
Davies, Kay E.
2015.
Second-generation compound for the modulation of utrophin in the therapy of DMD.
Human Molecular Genetics,
Vol. 24,
Issue. 15,
p.
4212.
Spinazzola, Janelle M.
and
Kunkel, Louis M.
2016.
Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy.
Expert Opinion on Orphan Drugs,
Vol. 4,
Issue. 11,
p.
1179.
Dufresne, Sébastien S.
Boulanger-Piette, Antoine
and
Frenette, Jérôme
2017.
Osteoprotegerin and β2-Agonists Mitigate Muscular Dystrophy in Slow- and Fast-Twitch Skeletal Muscles.
The American Journal of Pathology,
Vol. 187,
Issue. 3,
p.
498.
Kim, Jihee
Grotegut, Chad A.
Wisler, James W.
Li, Tianyu
Mao, Lan
Chen, Minyong
Chen, Wei
Rosenberg, Paul B.
Rockman, Howard A.
and
Lefkowitz, Robert J.
2018.
β-arrestin 1 regulates β2-adrenergic receptor-mediated skeletal muscle hypertrophy and contractility.
Skeletal Muscle,
Vol. 8,
Issue. 1,